We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Metablok

News List

Arch Biopartners to Proceed with Metablok Trial for COVID-19 americanpharmaceuticalreview
June 28, 2020
Arch Biopartners announced the U.S. Food and Drug Administration (FDA) has granted permission to the Company to proceed with a Phase II trial in the U.S. for its lead drug Metablok (LSALT peptide) to prevent acute lung and kidney injury experienced by ...
Arch Biopartners Expands Primary Endpoint of COVID-19 Trial americanpharmaceuticalreview
May 26, 2020
Arch Biopartners has expanded the primary endpoint of the Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation and injury experienced by patients with COVID-19.